---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-001431"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2025-09-04T23:59:59+00:00"
generated_at: "2026-05-17T08:14:02.758709+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical plans Phase 1/2 trials for NPM-139 semaglutide implant; H1 2026 start

## Summary
- NPM-139 is a semaglutide implant for chronic weight management in obese/overweight patients.
- Phase 1 study expected to start H1 2026 pending regulatory clearance; designed for safety, tolerability, PK.
- Phase 2 dose-ranging study planned to follow Phase 1, pending enabling results and regulatory feedback.
- NPM-139 aims to deliver Wegovy-level efficacy with once or twice-yearly administration.
- Positive preclinical data and promising LIBERATE-1 results for NPM-115 (exenatide) support program.

## SEC filing metadata
- accession: 0001753926-25-001431
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2025-09-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392625001431/0001753926-25-001431-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392625001431/vani-20250904.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-001431
- JSON: https://secwatch.observer/filing/0001753926-25-001431.json
- Plain text: https://secwatch.observer/filing/0001753926-25-001431.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.